Fighting Antibiotic Resistance: Going Public w James Graham
With Stake, Australia's leading investing platform, I'm excited to share the ninth episode of 'Going Public' - a new monthly series giving you unique access to the entrepreneurs, founders and executives who've taken their business public.
This podcast will delve into the journey of James Graham, one of the youngest CEOs in Australia's public company sector. At 34, James leads Recce Pharmaceuticals (ASX:RCE), a rapidly growing medical technology firm taking on antibiotic resistance, a global health crisis.
We explore the highs and lows of building a biotech company, the road to going public, and the impact of Recce's novel approach to fighting infectious diseases. Get insights into James' journey from startup entrepreneur to industry leader, his perspectives on global health, and his vision for making a lasting impact.
In 2016, Recce was listed on the Australian Securities Exchange with the stock ticker RCE.
DISCLAIMER:
Views expressed are those of the individual only. This does not constitute financial advice.
You can subscribe to the newsletter here: https://lnkd.in/e7C8akgj.
Follow Mark Bouris on Instagram, LinkedIn & YouTube.
See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.